0000899243-23-011461.txt : 20230419
0000899243-23-011461.hdr.sgml : 20230419
20230419194513
ACCESSION NUMBER: 0000899243-23-011461
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230417
FILED AS OF DATE: 20230419
DATE AS OF CHANGE: 20230419
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yeramian Patrick D
CENTRAL INDEX KEY: 0001358266
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41199
FILM NUMBER: 23831112
MAIL ADDRESS:
STREET 1: 1815 PARKSIDE CIRCLE SOUTH
CITY: BOCA RATON
STATE: FL
ZIP: 33486
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658551
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 464600503
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 617-683-0917
MAIL ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-04-17
0
0001658551
Amylyx Pharmaceuticals, Inc.
AMLX
0001358266
Yeramian Patrick D
C/O AMYLYX PHARMACEUTICALS, INC.
43 THORNDIKE STREET
CAMBRIDGE
MA
02141
0
1
0
0
Chief Medical Officer
1
Common Stock
2023-04-17
4
M
0
44861
0.37
A
253278
D
Common Stock
2023-04-17
4
M
0
4718
6.88
A
257996
D
Common Stock
2023-04-17
4
S
0
49279
30.5335
D
208717
D
Common Stock
2023-04-17
4
S
0
300
30.94
D
208417
D
Stock Option (right to buy)
0.37
2023-04-17
4
M
0
44861
0.00
D
2029-03-18
Common Stock
44861
17605
D
Stock Option (right to buy)
6.88
2023-04-17
4
M
0
4718
0.00
D
2031-02-21
Common Stock
4718
43534
D
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.93 to $30.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
As of the date of this filing, 44,861 shares subject to the option are vested and exercisable. 17,605 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023.
As of the date of this filing, 18,464 shares subject to the option are vested and exercisable. 29,788 shares subject to such option vest and become exercisable in substantially equal monthly installments until December 19, 2023.
/s/ Joshua B. Cohen, as Attorney in Fact
2023-04-19